Patents by Inventor Michael L. Hess

Michael L. Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histidine as a protective agent in cardiac surgery and myocardial ischemic syndromes
    Patent number: 5710172
    Abstract: Histidine has been found to be efficacious in preventing ischemic/reperfusion induced myocardial injury both functionally and ultrastructurally. Isolated perfused rat hearts (n=8/group) were subjected to 30 minutes of global ischemia and 20 minutes of reperfusion. Histidine concentrations ranging from 10 to 50 mM were given throughout the experiment. During ischemia and reperfusion without histidine the contractile function and coronary flow were 59.+-.10% and 78.+-.6% of control, respectively. Perfusion with histidine (25 mM and above) resulted in significant increases in contractility (94.+-.4%) and coronary flow (92.+-.4) levels. The incidence of arrhythmias (ventricular tachycardia and ventricular fibrillation) during reperfusion was 100 percent (8/8) in the ischemic/reperfused group with an average duration of 13.23.+-.4.48 min. The addition of 25 mM histidine to the perfusion medium reduced the incidence and duration of arrhythmias significantly (mean.+-.SEM 2.25.+-.0.98 min) (P<0.01).
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignee: CYTOS Pharmaceuticals, LLC
    Inventors: Rakesh C. Kukreja, Michael L. Hess
  • Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
    Patent number: 5280038
    Abstract: Histidine has been found to be efficacious in preventing ischemic/reperfusion induced myocardial injury both functionally and ultrastructurally. Isolated perfused rat hearts (n=8/group) were subjected to 30 minutes of global ischemia and 20 minutes of reperfusion. Histidine concentrations ranging from 10 to 50 mM were given throughout the experiment. During ischemia and reperfusion without histidine the contractile function and coronary flow were 59.+-.10% and 78.+-.6% of control, respectively. Perfusion with histidine (25 mM and above) resulted in significant increases in contractility (94.+-.4%) and coronary flow (92.+-.4) levels. The incidence of arrhythmias (ventricular tachycardia and ventricular fibrillation) during reperfusion was 100 percent (8/8) in the ischemic/reperfused group with an average duration of 13.23.+-.4.48 min. The addition of 25 mM histidine to the perfusion medium reduced the incidence and duration of arrhythmias significantly (mean.+-.SEM 2.25.+-.0.98 min) (P<0.01).
    Type: Grant
    Filed: March 13, 1992
    Date of Patent: January 18, 1994
    Assignee: Virginia Commonwealth University
    Inventors: Rakesh C. Kukreja, Michael L. Hess